Nurx, a San Francisco, CA-based healthtech company providing care for sensitive needs, raised an additional $52m in Series C funding.
The round was led by Kleiner Perkins Digital Growth Fund and Union Square Ventures with participation from Reproductive Health Investors Alliance, Dreamers VC, Lowercase Capital, and Y Combinator, as well as Triple Point Capital for equity and debt. In conjunction with the funding, public health leader Chelsea Clinton and Former U.S. Surgeon General Regina Benjamin, MD, MBA, joined Nurx’ board of directors.
The company intends to use the funds to:
- introduce more services for sensitive health needs,
- grow its patient community,
- expand its medical provider team, as well as
- invest in its telemedicine platform to continue improving and streamlining the patient experience.
Led by CEO Varsha Rao, Nurx is a health tech company providing personalized care for sensitive health needs. It offers contraception services, STI home test kits, as well as HIV prevention medication, providing PrEP to more than 6,000 patients across the country.
Nurx’s technology platform connects medical providers and pharmacies directly to patients in a single app in order to deliver care that eliminates access barriers to healthcare. After a patient shares their health history through the app, their medical provider will consult with the patient regarding their request within 1-2 days while the platform checks their insurance. If approved by the provider, medication and home testing kits arrive in discreet packaging at the patient’s home within 3-5 days. After their initial consultation or exam, patients also have access to their provider for one year, allowing them to ask as
many questions about their health condition as they’d like.
Nurx is available in 26 states and the District of Columbia.